MRKR VS NRXP Stock Comparison

Performance

MRKR
10/100

MRKR returned -20.79% in the last 12 months. Based on SPY's performance of -13.80%, its performance is below average giving it a score of 10 of 100.

NRXP
10/100

NRXP returned -62.74% in the last 12 months. Based on SPY's performance of -21.23%, its performance is below average giving it a score of 10 of 100.

Technicals

MRKR
21/100

MRKR receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

NRXP
64/100

NRXP receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

MRKR
10/100

MRKR has missed earnings 6 times in the last 20 quarters.

NRXP
49/100

NRXP has missed earnings 2 times in the last 20 quarters.

Profit

MRKR
10/100

Out of the last 20 quarters, MRKR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

NRXP
19/100

Out of the last 20 quarters, NRXP has had 6 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

MRKR
58/100

MRKR has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

NRXP
41/100

NRXP has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

Sentiment

MRKR

"Sentiment" not found for MRKR

NRXP
69/100

NRXP had a bullish sentiment score of 69.38% across Twitter and StockTwits over the last 12 months. It had an average of 26.28 posts, 15.67 comments, and 77.44 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Marker Therapeutics, Inc. Common Stock Summary

Nasdaq / MRKR

Healthcare

Biotechnology

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

NRX Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / NRXP

Healthcare

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Power up your portfolio